Connection

Dennis Watson to Genetic Vectors

This is a "connection" page, showing publications Dennis Watson has written about Genetic Vectors.
Connection Strength

0.103
  1. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol. 2000 Aug; 20(15):5643-52.
    View in: PubMed
    Score: 0.041
  2. Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancer. Mol Ther. 2006 Feb; 13(2):357-65.
    View in: PubMed
    Score: 0.015
  3. CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer. Anticancer Res. 2003 May-Jun; 23(3A):2007-13.
    View in: PubMed
    Score: 0.013
  4. The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer. Surgery. 2000 Aug; 128(2):353-60.
    View in: PubMed
    Score: 0.010
  5. Increased expression of the ETS-related transcription factor FLI-1/ERGB correlates with and can induce the megakaryocytic phenotype. Cell Growth Differ. 1996 Nov; 7(11):1525-34.
    View in: PubMed
    Score: 0.008
  6. The EndoA enhancer contains multiple ETS binding site repeats and is regulated by ETS proteins. Oncogene. 1994 Feb; 9(2):469-77.
    View in: PubMed
    Score: 0.007
  7. c-ets-2 protooncogene has mitogenic and oncogenic activity. Proc Natl Acad Sci U S A. 1989 Oct; 86(20):7833-7.
    View in: PubMed
    Score: 0.005
  8. Expression of human and viral ets genes in E. coli production of human ets-2-specific monoclonal antibodies. Oncogene Res. 1989; 5(1):61-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.